Biotechnology

MiMedx

MiMedx released FY2026 Q1 earnings on April 29 After-Market EST, actual revenue USD 58.99 M (forecast USD 65.8 M), actual EPS USD -0.0731 (forecast USD -0.0433)

MiMedx to Release FY2026 Q1 Earnings on April 29 After-Market EST, Forecast Revenue USD 65.8 M, EPS USD -0.0433

MiMedx released FY2025 earnings on February 25 After-Market EST, actual revenue USD 418.63 M (forecast USD 407.31 M), actual EPS USD 0.3199 (forecast USD 0.3333)

MiMedx released FY2025 Q4 earnings on February 25 After-Market EST, actual revenue USD 118.1 M (forecast USD 106.78 M), actual EPS USD 0.0999 (forecast USD 0.0883)

MiMedx to Release FY2025 Q4 Earnings on February 25 After-Market EST, Forecast Revenue USD 106.93 M, EPS USD 0.09

Analyst Maintains Buy Rating for MiMedx Group

Northern Securities Analyst Maintains Buy Rating for MiMedx Group

MiMedx Group Receives Multiple Firm Ratings

MiMedx Group Reports Exceeding EPS, Stock Price Rises

Analyst Knickerbocker and Lake Street give MiMedx Group a Buy Rating

MiMedx released FY2025 9 Months Earnings on October 29 After-Market EST, actual revenue USD 300.54 M, actual EPS USD 0.2176

MiMedx released FY2025 Q3 earnings on October 29 After-Market (EST), actual revenue USD 113.73 M (forecast USD 94.74 M), actual EPS USD 0.11 (forecast USD 0.0625)

MiMedx to Release FY2025 Q3 Earnings on October 29 After-Market (EST), Forecast Revenue USD 94.74M, EPS USD 0.0625

Knickerbocker Reiterates Strong Buy Rating on MiMedx Group with $12.00 Price Target

MiMedx released FY2025 Q2 earnings on July 30 After-Market (EST), actual revenue USD 98.61 M (forecast USD 90.79 M), actual EPS USD 0.06 (forecast USD 0.0533)

MiMedx released FY2025 Semi-Annual earnings on July 30 After-Market (EST), actual revenue USD 186.81 M, actual EPS USD 0.11

MiMedx to Release FY2025 Q2 Earnings on July 30 After-Market EST, Forecast Revenue USD 90.79 M, EPS USD 0.0533

MiMedx Supports 2026 Medicare Reimbursement Reform

Cantor Fitzgerald Reiterates MiMedx Group 'Outperform' Rating

James Bierman Buys MiMedx Group Stocks

OPTIMI HEALTH CORP

HCW Biologics

Silexion Therapeutics

Vida Global

GCL Global

BiomX

MetaVia

Micware

MicroAlgo

MDXG

Pomerantz Law Firm is investigating claims on behalf of investors of MiMedx Group, Inc. (NASDAQ: MDXG) regarding potential securities fraud or unlawful business practices. MiMedx recently reported Q1 2026 financial results, missing earnings and revenue estimates, leading to a 9.26% drop in stock price. Investors are encouraged to contact Pomerantz for more information.

prnewswire

23:01 ETINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of MiMedx Group, Inc. - MDXG

MiMedx Group (MDXG) received a Buy rating from Mizuho Securities, with a price target of $8.00, while shares closed at $3.36. Analyst Anthony Petrone has a 4.0% average return and a 45.55% success rate. The consensus rating for MiMedx is a Strong Buy, with an average price target of $6.83, indicating a 103.27% upside. Craig-Hallum also assigned a Buy rating with a $6.00 price target.

Tip Ranks

Mizuho Financial

Pulse Biosciences

Heamonetics

Boston Scientific

Mizuho Financial Group, Inc.

MiMedx Group (MDXG) Receives a Buy from Mizuho Securities

Earnings Watch

MiMedx | 8-K: FY2026 Q1 Revenue Misses Estimate at USD 58.99 M

MiMedx Group shares are trading lower after the company reported worse-than-expected Q1 financial results and lowered its FY2026 sales guidance.

benzinga_article

Citizens Jmp has reaffirmed a "market outperform" rating for MiMedx Group (NASDAQ:MDXG) with a revised price target of $7.00, down from $10.00. This target suggests a potential upside of 105.28% from the current stock price. Other analysts have also adjusted their ratings and price targets for MiMedx Group, with a consensus rating of "Moderate Buy" and an average target price of $8.67. The company reported a quarterly EPS of $0.14, exceeding estimates, and has a market cap of $506.62 million.

Market Beat

Citizens Jmp Reaffirms "Market Outperform" Rating for MiMedx Group (NASDAQ:MDXG)

Investment analysts at Northland Securities have reduced their Q3 2026 EPS estimates for MiMedx Group (NASDAQ:MDXG) from $0.03 to $0.00. The consensus estimate for the company's full-year earnings is $0.30 per share. MiMedx Group recently reported Q4 earnings of $0.14 per share, exceeding expectations. The stock is currently rated as "Moderate Buy" with a target price of $9.17. MiMedx Group specializes in regenerative biomaterial products derived from human placental tissues, focusing on wound healing and surgical applications.

MiMedx Group Q3 EPS Estimate Reduced by Northland Securities

MiMedx Group, Inc. (MDXG) has announced the elimination of the Chief Operating Officer position and plans to implement cost reduction strategies aimed at saving approximately $40 million. The company expects a one-time restructuring charge of about $4 million in Q2 2026. MiMedx aims to focus on growth opportunities and streamline operations, while its surgical business is performing well despite slow recovery in the wound care sector due to recent Medicare reimbursement changes.

rttnews

MiMedx Expects Approx. $40 Mln Through Restructuring, Eliminates COO Position

MiMedx Group shares are trading lower after the company announced a restructuring and cost-cutting plans.

MiMedx(MDXG.US)